Dalbavancin

[{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Centre Hospitalier de Perigueux | Advanz Pharma | Nantes University Hospital | Centre National de R\u00e9f\u00e9rence des staphylocoques","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Centre Hospitalier de Perigueux | Advanz Pharma | Nantes University Hospital | Centre National de R\u00e9f\u00e9rence des staphylocoques","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Centre Hospitalier de Perigueux | Advanz Pharma | Nantes University Hospital | Centre National de R\u00e9f\u00e9rence des staphylocoques"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Foundation for Barnes-Jewish Hospital | Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Foundation for Barnes-Jewish Hospital | Allergan","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Foundation for Barnes-Jewish Hospital | Allergan"},{"orgOrder":0,"company":"Infectious Diseases Physicians","sponsor":"Johns Hopkins University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Infectious Diseases Physicians","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Infectious Diseases Physicians \/ Johns Hopkins University","highestDevelopmentStatusID":"11","companyTruncated":"Infectious Diseases Physicians \/ Johns Hopkins University"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"}]

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Virtual Booth

Contact Supplier

Check COS database
Check all USDMF suppliers

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

25 API Suppliers, 7 USDMF, 4 NDC API, 17 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

11 FDF Dossiers, 1 FDA Orange Book, 10 Europe

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 13 SPI Pharma, 3 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 BASF, 2 DFE Pharma, 2 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 10 Kerry, 4 Microlex e.U, 2 Pluviaendo, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 2 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

26 Fillers, Diluents & Binders, 15 Direct Compression, 12 Chewable & Orodispersible Aids, 10 Granulation, 10 Taste Masking, 7 Disintegrants & Superdisintegrants, 5 Co-Processed Excipients, 5 Parenteral, 1 Solubilizers, 1 Thickeners and Stabilizers

DIGITAL CONTENT

12 News #PharmaBuzz

12 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 1 Regulatory FDF Prices, 4 Annual Reports

MARKET PLACE

9 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

1 US Patents, 2 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 Others

1 Others

Xls

Filters

Company Name

Year

DEALS // DEV.

Country

Sponsor

Therapeutic Area

Study Phase

Deal Type

Product Type

Dosage Form

Lead Product

Target

Filters

Reset Filter

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

AbbVie Inc

U.S.A

AIChE Annual Meeting

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Approved FDF

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

DALVANCE FDA Approval Acute Bacterial Skin Structure Infections in Pediatric

Details : The 5 patients in the age group birth to less than 3 months of age were not included in the efficacy analyses since they were enrolled with expanded inclusion criteria and only received the single-dose DALVANCE regimen.

Product Name : Dalvance

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

July 23, 2021

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

02

AbbVie Inc

U.S.A

AIChE Annual Meeting

Not Confirmed

Lead Product(s) : Dalbavancin

Therapeutic Area : Cardiology/Vascular Diseases

Study Phase : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treat...

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Endocarditis.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

May 11, 2017

Lead Product(s) : Dalbavancin

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

03

AbbVie Inc

U.S.A

AIChE Annual Meeting

Not Confirmed

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Susp...

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Methicillin-Resistant Staphylococcus aureus.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

June 28, 2016

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

04

AbbVie Inc

U.S.A

AIChE Annual Meeting

Not Confirmed

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase I

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacteria...

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Bacterial Infections.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

February 23, 2016

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

05

AbbVie Inc

U.S.A

AIChE Annual Meeting

Not Confirmed

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyeli...

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteomyelitis.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

February 18, 2016

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

06

AbbVie Inc

U.S.A

AIChE Annual Meeting

Not Confirmed

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

A P3 Comparator Trial in Community Acquired Bacterial Pneumonia

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Community-Acquired Pneumonia.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

October 21, 2014

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

07

AbbVie Inc

U.S.A

AIChE Annual Meeting

Not Confirmed

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure I...

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Abscess.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

May 01, 2014

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

08

AbbVie Inc

U.S.A

AIChE Annual Meeting

Not Confirmed

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase I

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Age...

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Bacterial Infections.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

September 19, 2013

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow